Article

Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med

Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
New England Journal of Medicine (Impact Factor: 54.42). 07/2008; 358(25):2698-703. DOI: 10.1056/NEJMoa0800251
Source: PubMed

ABSTRACT We developed an in vitro method for isolating and expanding autologous CD4+ T-cell clones with specificity for the melanoma-associated antigen NY-ESO-1. We infused these cells into a patient with refractory metastatic melanoma who had not undergone any previous conditioning or cytokine treatment. We show that the transferred CD4+ T cells mediated a durable clinical remission and led to endogenous responses against melanoma antigens other than NY-ESO-1.

Download full-text

Full-text

Available from: Cassian Yee, Aug 22, 2015
0 Followers
 · 
225 Views
  • Source
    • "umor responses following administration of various immunotherapeutic strategies in the absence of cytoablative treat - ments , and have suggested that such responses are likely due to the balance between effector T cells ( i . e . , either CD4 or CD8 ) and TReg cells within treated cancer patients ( Alvaro et al . , 2005 ; Quezada et al . , 2006 ; Hunder et al . , 2008 ; Le and Jaffee , 2012 ; Liu et al . , 2012a ) . Along these lines , in our clinical study investigating adop - tive T cell therapy using autologous Th1 - like effector cells in the treatment of ovarian cancer patients , we observed enhanced T cell - mediated immune responses in long - term surviving patients that appeared to correlate "
    [Show abstract] [Hide abstract]
    ABSTRACT: The importance of CD4 T cells in orchestrating the immune system and their role in inducing effective T cell-mediated therapies for the treatment of patients with select established malignancies are undisputable. Through a complex and balanced array of direct and indirect mechanisms of cellular activation and regulation, this functionally diverse family of lymphocytes can potentially promote tumor eradication, long-term tumor immunity, and aid in establishing and/or rebalancing immune cell homeostasis through interaction with other immune cell populations within the highly dynamic tumor environment. However, recent studies have uncovered additional functions and roles for CD4 T cells, some of which are independent of other lymphocytes, that can not only influence and contribute to tumor immunity but paradoxically promote tumor growth and progression. Here, we review the recent advances in our understanding of the various CD4 T cell lineages and their signature cytokines in disease progression and/or regression. We discuss their direct and indirect mechanistic interplay among themselves and with other responding cells of the antitumor response, their potential roles and abilities for "plasticity" and memory cell generation within the hostile tumor environment, and their potentials in cancer treatment and immunotherapy.
    Frontiers in Oncology 03/2013; 3:63. DOI:10.3389/fonc.2013.00063
  • Source
    • "Aberrant CTA expression was first described in melanoma; as such, this expression was found to generate CTA-specific cytotoxic T-cell responses [47]. Recently, it was reported that treatment of metastatic melanoma with autologous CD4 + T cells specific for the CTA, NY-ESO- 1, elicited long-term complete remission [48]. In addition to melanoma, CTA expression has also been observed in hematological malignancies [49] as well as solid tumors, including breast cancer [50] [51]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The advancement of cancer immunotherapy faces barriers which limit its efficacy. These include weak immunogenicity of the tumor, as well as immunosuppressive mechanisms which prevent effective antitumor immune responses. Recent studies suggest that aberrant expression of cancer testis antigens (CTAs) can generate robust antitumor immune responses, which implicates CTAs as potential targets for immunotherapy. However, the heterogeneity of tumor cells in the presence and quantity of CTA expression results in tumor escape from CTA-specific immune responses. Thus, the ability to modulate the tumor cell epigenome to homogenously induce expression of such antigens will likely render the tumor more immunogenic. Additionally, emerging studies suggest that suppression of antitumor immune responses may be overcome by reprogramming innate and adaptive immune cells. Therefore, this paper discusses recent studies which address barriers to successful cancer immunotherapy and proposes a strategy of modulation of tumor-immune cell crosstalk to improve responses in carcinoma patients.
    Clinical and Developmental Immunology 10/2012; 2012:760965. DOI:10.1155/2012/760965 · 2.93 Impact Factor
  • Source
    • "CTA offer such a target, and have been subject of intense study because of their aberrant expression in a variety of tumours. In patients with malignant melanoma, CTAG1B reactive T cells have been isolated and expanded ex vivo and re-infused into autologous recipients with dramatic responses recorded (Hunder et al, 2008). Recently, in vitro evidence of CTA overexpression by epigenetic modification and an adaptive T cell response has been demonstrated against MAGEA4 in patients with Hodgkin lymphoma treated with decitabine (Cruz et al, 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Patients with multiple myeloma (MM) undergoing high dose therapy and autologous stem cell transplantation (SCT) remain at risk for disease progression. Induction of the expression of highly immunogenic cancer testis antigens (CTA) in malignant plasma cells in MM patients may trigger a protective immune response following SCT. We initiated a phase II clinical trial of the DNA hypomethylating agent, azacitidine (Aza) administered sequentially with lenalidomide (Rev) in patients with MM. Three cycles of Aza and Rev were administered and autologous lymphocytes were collected following the 2nd and 3rd cycles of Aza-Rev and cryopreserved. Subsequent stem cell mobilization was followed by high-dose melphalan and SCT. Autologous lymphocyte infusion (ALI) was performed in the second month following transplantation. Fourteen patients have completed the investigational therapy; autologous lymphocytes were collected from all of the patients. Thirteen patients have successfully completed SCT and 11 have undergone ALI. Six patients tested have demonstrated CTA up-regulation in either unfractionated bone marrow (n = 4) or CD138+ cells (n = 2). CTA (CTAG1B)-specific T cell response has been observed in all three patients tested and persists following SCT. Epigenetic induction of an adaptive immune response to cancer testis antigens is safe and feasible in MM patients undergoing SCT.
    British Journal of Haematology 07/2012; 158(6):700-11. DOI:10.1111/j.1365-2141.2012.09225.x · 4.96 Impact Factor
Show more